These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29175298)

  • 1. Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?
    Samoš M; Bolek T; Stančiaková L; Škorňová I; Ivanková J; Kovář F; Galajda P; Kubisz P; Staško J; Mokáň M
    Diabetes Res Clin Pract; 2018 Jan; 135():172-177. PubMed ID: 29175298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
    Nosáľ V; Petrovičová A; Škorňová I; Bolek T; Dluhá J; Stančiaková L; Sivák Š; Babálová L; Hajaš G; Staško J; Kubisz P; Kurča E; Samoš M; Mokáň M
    Eur J Clin Pharmacol; 2022 Apr; 78(4):557-564. PubMed ID: 35066599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study.
    Škorňová I; Samoš M; Bolek T; Kamenišťáková A; Stančiaková L; Galajda P; Staško J; Kubisz P; Mokáň M
    J Cardiovasc Pharmacol; 2021 Jul; 78(1):e122-e127. PubMed ID: 34173805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
    Samoš M; Bolek T; Stančiaková L; Škorňová I; Bánovčin P; Kovář F; Staško J; Galajda P; Kubisz P; Mokáň M
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):369-373. PubMed ID: 29538002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.
    Bolek T; Samoš M; Škorňová I; Stančiaková L; Staško J; Korpallová B; Galajda P; Kubisz P; Mokáň M
    J Thromb Thrombolysis; 2019 Jan; 47(1):140-145. PubMed ID: 30288664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 9. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual anticoagulation activity in atrial fibrillation patients with temporary interrupted direct oral anticoagulants: Comparisons across 4 drugs.
    Sairaku A; Nakano Y; Onohara Y; Hironobe N; Matsumura H; Shimizu W; Kihara Y
    Thromb Res; 2019 Nov; 183():119-123. PubMed ID: 31677591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New oral anticoagulants for atrial fibrillation: a review of clinical trials.
    O'Dell KM; Igawa D; Hsin J
    Clin Ther; 2012 Apr; 34(4):894-901. PubMed ID: 22417716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation.
    Fanning L; Ilomäki J; Bell JS; Dārziņš P
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1427-1436. PubMed ID: 28752255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
    Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
    Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.